Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

2XF0

Crystal structure of checkpoint kinase 1 (Chk1) in complex with inhibitors

Summary for 2XF0
Entry DOI10.2210/pdb2xf0/pdb
Related1IA8 1NVQ 1NVR 1NVS 1ZLT 1ZYS 2AYP 2BR1 2BRB 2BRG 2BRH 2BRM 2BRN 2BRO 2C3J 2C3K 2C3L 2CGU 2CGV 2CGW 2CGX 2WMQ 2WMR 2WMS 2WMT 2WMU 2WMV 2WMW 2WMX 2X8D 2X8E 2X8I 2XEY 2XEZ
DescriptorSERINE/THREONINE-PROTEIN KINASE CHK1, 3-PHENYL-6-(1H-PYRAZOL-4-YL)IMIDAZO[1,2-A]PYRAZINE, 1,2-ETHANEDIOL, ... (4 entities in total)
Functional Keywordstransferase, dna repair, cell cycle
Biological sourceHOMO SAPIENS (HUMAN)
Cellular locationNucleus: O14757
Total number of polymer chains1
Total formula weight33552.54
Authors
Primary citationMatthews, T.P.,Mchardy, T.,Klair, S.,Boxall, K.,Fisher, M.,Cherry, M.,Allen, C.E.,Addison, G.J.,Ellard, J.,Aherne, G.W.,Westwood, I.M.,Montfort, R.V.,Garrett, M.D.,Reader, J.C.,Collins, I.
Design and Evaluation of 3,6-Di(Hetero)Aryl Imidazo[1,2-A]Pyrazines as Inhibitors of Checkpoint and Other Kinases.
Bioorg.Med.Chem.Lett., 20:4045-, 2010
Cited by
PubMed Abstract: A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with improved potency and ligand efficiency against CHK1. Kinase profiling showed that the imidazo[1,2-a]pyrazines could inhibit other kinases, including CHK2 and ABL, with equivalent or better potency depending on the pendant substitution. These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold.
PubMed: 20561787
DOI: 10.1016/J.BMCL.2010.05.096
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon